V
domain
Immunoglobulin
suppressor
of
T
cell
activation
(VISTA)
has
been
proved
to
be
a
novel
immune
checkpoint
molecule
that
positively
regulates
infiltration
in
several
malignancies.
However,
the
clinical
impact
VISTA
on
muscle-invasive
bladder
cancer
(MIBC)
patients
remains
relatively
obscure.This
study
enrolled
135
MIBC
from
Zhongshan
Hospital
(ZSHS)
and
391
The
Cancer
Genome
Atlas
(TCGA)
examine
expression
contexture
based
immunohistochemistry
(IHC)
staining
CIBERSORT
algorithm.
Additionally,
IMvigor210
Cohort
included
195
bladder-derived
urothelial
carcinoma
evaluate
efficacy
immunotherapy.
Kaplan-Meier
curve
Cox
regression
analyses
were
conducted
assess
outcomes.MIBC
with
high
VISTA+
cells
(ICs)
possessed
poor
overall
survival
inferior
therapeutic
responsiveness
adjuvant
chemotherapy
(ACT),
but
superior
PD-L1
inhibitor.
ICs
shaped
an
immunoevasive
context
featured
by
regulatory
(Tregs),
M2
macrophages,
mast
exhausted
CD8+
infiltration,
increased
interleukin
10
(IL-10),
transforming
growth
factor-β
(TGF-β)
interferon-γ
(IFN-γ),
also
elevated
T-cell
immunoglobulin
mucin-3
(TIM-3),
lymphocyte
gene
3
(LAG-3)
ITIM
(TIGIT),
which
was
mainly
presented
basal-squamous
luminal-infiltrated
subtypes
MIBC.VISTA+
could
independent
predictor
identify
prognosis
responses
(PD-L1
blockade
ACT)
patients,
associated
contexture.
might
utilized
as
candidate
treatment
biomarker
patients.
Biomedicine & Pharmacotherapy,
Год журнала:
2023,
Номер
163, С. 114890 - 114890
Опубликована: Май 15, 2023
B7
homolog
3
(B7-H3,
also
called
CD276)
is
a
checkpoint
of
family
that
aberrantly
and
consistently
expressed
in
several
human
cancers,
its
overexpression
correlates
with
weak
prognosis.
B7-H3
on
number
cells,
it
acts
as
driver
immune
evasion.
This
mediated
through
hampering
T
cell
infiltration
promoting
exhaustion
CD8+
cells.
Increased
activity
promotes
macrophage
polarity
toward
pro-tumor
type
2
(M2)
phenotype.
In
addition,
high
induces
aberrant
angiogenesis
to
promote
hypoxia,
result
which
resistance
common
inhibitor
(ICI)
therapy.
the
impact
hypoxia
dampening
recruitment
into
tumor
area.
The
immunosuppressive
property
offers
insights
targeting
this
desired
approach
cancer
immunotherapy.
can
be
target
blocking
monoclonal
antibodies
(mAbs),
combination
therapies,
chimeric
antigen
receptor-modified
(CAR-T)
cells
bispecific
antibodies.
Frontiers in Immunology,
Год журнала:
2023,
Номер
13
Опубликована: Янв. 16, 2023
Myeloid
derived
suppressors
cells
(MDSC)
play
major
roles
in
regulating
immune
homeostasis
and
responses
many
conditions,
including
cancer.
MDSC
interact
with
cancer
within
the
tumor
microenvironment
(TME)
direct
indirect
mechanisms:
production
of
soluble
factors
cytokines,
expression
surface
inhibitory
molecules,
metabolic
rewiring
exosome
release.
The
two-way
relationship
between
results
evasion
outgrowth.
In
multiple
myeloma
(MM),
a
role
creating
protumoral
TME
conditions.
this
minireview,
we
will
discuss
interplay
MM
possible
strategies
to
target
MDSC.
Biomedicine & Pharmacotherapy,
Год журнала:
2023,
Номер
167, С. 115514 - 115514
Опубликована: Сен. 15, 2023
Programmed
cell
death
protein-1
(PD-1),
also
called
CD279,
is
coded
by
the
PDCD1
gene
and
constitutively
expressed
on
surface
of
immune
cells.
As
a
receptor
checkpoint,
PD-1
can
bind
to
programmed
ligand-1/programmed
ligand-2
(PD-L1/PD-L2)
in
tumor
cells,
leading
evasion.
Anti-PD-1
anti-PD-L1
are
important
components
therapy.
as
an
intrinsic
variant
(iPD-1)
cancer
cells
where
it
plays
roles
malignant
progression
proposed
recent
studies.
However,
iPD-1
has
received
much
less
attention
compared
although
there
unmet
medical
need
for
fully
elucidating
mechanisms
actions
achieve
best
response
immunotherapy.
suppresses
tumorigenesis
non-small
lung
(NSCLC)
colon
cancer,
whereas
promotes
melanoma,
hepatocellular
carcinoma
(HCC),
pancreatic
ductal
adenocarcinoma
(PDAC),
thyroid
(TC),
glioblastoma
(GBM),
triple-negative
breast
(TNBC).
In
this
review,
we
focus
role
development
its
molecular
mechanisms.
We
deeply
discuss
nivolumab-based
combined
therapy
common
may
explain
different
therapeutic
effects
anti-PD-1
treatment
provide
critical
information
use
anti-tumor
approaches.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Март 4, 2024
Immunotherapies
have
revolutionized
the
landscape
of
cancer
treatment.
Regulatory
T
cells
(Tregs),
as
crucial
components
tumor
immune
environment,
has
great
therapeutic
potential.
However,
nonspecific
inhibition
Tregs
in
therapies
may
not
lead
to
enhanced
antitumor
responses,
but
could
also
trigger
autoimmune
reactions
patients,
resulting
intolerable
treatment
side
effects.
Hence,
precision
targeting
and
tumor-infiltrating
is
paramount
importance.
In
this
overview,
we
summarize
characteristics
subpopulations
within
microenvironment
their
inhibitory
mechanisms
responses.
Furthermore,
discuss
current
major
strategies
regulatory
cells,
weighing
advantages
limitations,
representative
clinical
trials
We
believe
that
developing
specifically
target
suppress
holds
promise
for
advancing
immune-based
therapies.
Cell Death Discovery,
Год журнала:
2023,
Номер
9(1)
Опубликована: Ноя. 24, 2023
Abstract
MicroRNAs
(miRNAs)
are
a
class
of
non-coding
RNAs
(ncRNAs)
with
short
length
19–22
nucleotides.
miRNAs
posttranscriptional
regulators
gene
expression
involved
in
various
biological
processes
like
cell
growth,
apoptosis,
and
angiogenesis.
miR-184
is
well-studied
miRNA,
for
which
most
studies
report
its
downregulation
cancer
cells
tissues
experiments
support
role
as
tumor
suppressor
inhibiting
malignant
behaviors
vitro
vivo.
To
exert
functions,
affects
some
signaling
pathways
tumorigenesis
Wnt
β-catenin,
AKT/mTORC1
pathway,
oncogenic
factors
(e.g.,
c-Myc)
or
apoptotic
proteins,
such
Bcl-2.
Interestingly,
clinical
investigations
have
shown
good
performance
prognostic/diagnostic
biomarker
cancers.
Additionally,
exogenous
xenograft
animal
suggest
it
therapeutic
anticancer
target.
In
this
review,
we
outline
the
that
evaluated
roles
well
significance.
